Advertising Exhibitor&#x27;s Gallery

Driving Diversity with the Integrated Research Model

Recent analysis showed 81% of clinical trial sites using RBQM statistical data monitoring experienced an improvement in quality.

October 16th 2024

Palatin Announces Positive Results From Phase IIb BREAKOUT Study

Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.

© Minerva Studio - © Minerva Studio - stock.adobe.com

December 19th 2024

AI in Clinical Trials: A Long, But Promising Road Ahead

In patients with type 2 diabetic nephropathy, bremelanotide demonstrated efficacy in reducing urine protein to creatinine ratio and improving or stabilizing estimated glomerular filtration rate.

Miranda Schmalfuhs

May 29th 2024

Teva and Sanofi Share Positive Results from Phase II Study in Ulcerative Colitis and Crohn’s Disease

Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.

© Sebastian Kaulitzki - © Sebastian Kaulitzki - stock.adobe.com..

Imlunestrant Both as Monotherapy and in Combination Shows Promising Survival Benefits for ER-Positive, HER2-Negative Advanced Breast Cancer

Duvakitug, a monoclonal antibody, demonstrated clinical remission and endoscopic response in the study, meeting its primary endpoints.

Davy James

Using Data Patterns to Proactively Improve Study Quality

Results from the EMBER-3 trial show imlunestrant, both as monotherapy and in combination with Verzenio (abemaciclib), significantly improved progression-free survival in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Related Content

Sylviane de Viron;Steve Young

December 20th 2024

Driving Diversity with the Integrated Research Model

Recent analysis showed 81% of clinical trial sites using RBQM statistical data monitoring experienced an improvement in quality.

October 16th 2024

Palatin Announces Positive Results From Phase IIb BREAKOUT Study

December 19th 2024

AI in Clinical Trials: A Long, But Promising Road Ahead

In patients with type 2 diabetic nephropathy, bremelanotide demonstrated efficacy in reducing urine protein to creatinine ratio and improving or stabilizing estimated glomerular filtration rate.

Miranda Schmalfuhs

May 29th 2024

Teva and Sanofi Share Positive Results from Phase II Study in Ulcerative Colitis and Crohn’s Disease

Imlunestrant Both as Monotherapy and in Combination Shows Promising Survival Benefits for ER-Positive, HER2-Negative Advanced Breast Cancer

Duvakitug, a monoclonal antibody, demonstrated clinical remission and endoscopic response in the study, meeting its primary endpoints.

Davy James